edgen-logo
Search

Alpha Picks

Discover

Portfolio

News

Task Center

Chat History
Follow our

Join our

EN
Back
Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
Back
Stock NewsThemesSyndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress

Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress

Edgen StockEdgen Stock·Sep 13 2025, 22:02
Share to
Share to
Copy link
Syndax Pharmaceuticals Gains on Strong Revuforj Sales and Regulatory Progress
source:
[1] Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC[2] Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update[3] Stifel resumes Syndax Pharmaceuticals stock coverage with Buy rating - Investing.com
Recommend
Apple Stock Climbs as Investors Shun Big Tech's $650B AI SpendingFeb 18 2026, 00:32Similarweb Swings to Profit, Beating Q4 EstimatesFeb 17 2026, 23:58Hormel Sells Turkey Business, Reaffirms 2026 GuidanceFeb 17 2026, 23:57
Hot NewsTesla Produces First Cybercab, Advancing Robotaxi NetworkTesla Produces First Cybercab, Advancing Robotaxi NetworkFeb 18 2026, 01:06Hecla Mining Q4 EPS Soars 375%, Crushing EstimatesHecla Mining Q4 EPS Soars 375%, Crushing EstimatesFeb 18 2026, 00:59Caterpillar Acquires RPMGlobal to Expand Mining Software UnitCaterpillar Acquires RPMGlobal to Expand Mining Software UnitFeb 18 2026, 00:58Software Firms Release Early Data to Counter AI Debt RoutSoftware Firms Release Early Data to Counter AI Debt RoutFeb 18 2026, 00:38

Features
AI Copilot for Stock & Crypto
Price Prediction
Fundraise Tracker
Themes
Crypto Comparison
Home Page
Resources
Tutorial
Gitbook
Team
Aura Insights
Market
US Market
HK Market
Crypto Market
Terms of UsePrivacy PolicySitemap
© 2026 Finture Development Limited. All rights reserved